Imiquimod + zalifrelimab is under clinical development by UroGen Pharma and currently in Phase I for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer). According to GlobalData, Phase I drugs for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) have an 88% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Imiquimod + zalifrelimab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Imiquimod + zalifrelimab overview
UGN-302, a combination of imiquimod and zalifrelimab is under development for the treatment of high-grade non-muscle invasive bladder cancer (HG NMIBC) and prostate cancer. It is administered through the intravesical route. Imiquimod acts by targeting toll-like receptor 7 (TLR-7). Zalifrelimab acts by targeting cytotoxic T lymphocyte protein 4 (CTLA4).
UroGen Pharma overview
UroGen Pharma, formerly TheraCoat, is a biotechnology company that develops and commercializes novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs and Jelmyto for pyelocalyceal solution. The company pipeline products include UGN-102, which treats non-muscle invasive urothelial cancer; UGN-301 for High-grade non-muscle-invasive bladder cancer. UroGen Pharma is headquartered in Ra Anana, Israel.
For a complete picture of Imiquimod + zalifrelimab’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
